Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Quick facts
Marketed products
- aMIL · Oncology
aMIL is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations. - Contrave · Other
- Lupron · Other
- Rabbit antithymocyte globulin
- Taxotere · Oncology
- Xeloda · Oncology
Phase 3 pipeline
- Azacitadine · Other
- Cisplatin + Gemcitabine · Oncology
Cisplatin and gemcitabine work together as a chemotherapy combination to damage cancer cell DNA and inhibit nucleotide synthesis, leading to cell death.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: